Apollomics Class A Stock Net Income
| APLM Stock | 17.92 1.95 9.81% |
As of the 29th of January, Apollomics shows the Standard Deviation of 9.58, mean deviation of 6.94, and Risk Adjusted Performance of 6.0E-4. Apollomics Class A technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Apollomics Class A variance and potential upside to decide if Apollomics Class A is priced correctly, providing market reflects its regular price of 17.92 per share. Given that Apollomics has information ratio of (0.02), we suggest you to validate Apollomics Class A's prevailing market performance to make sure the company can sustain itself at a future point.
Apollomics Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 4.5565 | Revenue | Earnings Share (52.80) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -48.5 M | -50.9 M | |
| Net Loss | -48.5 M | -50.9 M | |
| Net Loss | (66.85) | (70.19) | |
| Net Income Per E B T | 0.90 | 0.80 |
Apollomics | Net Income | Build AI portfolio with Apollomics Stock |
Latest Apollomics' Net Income Growth Pattern
Below is the plot of the Net Income of Apollomics Class A over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Apollomics Class A financial statement analysis. It represents the amount of money remaining after all of Apollomics Class A operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Apollomics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Apollomics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (53.86 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Apollomics Net Income Regression Statistics
| Arithmetic Mean | (70,312,059) | |
| Coefficient Of Variation | (77.28) | |
| Mean Deviation | 35,503,619 | |
| Median | (45,905,000) | |
| Standard Deviation | 54,333,750 | |
| Sample Variance | 2952.2T | |
| Range | 194.9M | |
| R-Value | (0.39) | |
| Mean Square Error | 2663.8T | |
| R-Squared | 0.15 | |
| Significance | 0.12 | |
| Slope | (4,223,590) | |
| Total Sum of Squares | 47234.5T |
Apollomics Net Income History
Other Fundumenentals of Apollomics Class A
Apollomics Net Income component correlations
Apollomics Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Apollomics is extremely important. It helps to project a fair market value of Apollomics Stock properly, considering its historical fundamentals such as Net Income. Since Apollomics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Apollomics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Apollomics' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Apollomics diversify its offerings? Factors like these will boost the valuation of Apollomics. If investors know Apollomics will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Apollomics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (52.80) | Revenue Per Share | Quarterly Revenue Growth 2.623 | Return On Assets | Return On Equity |
The market value of Apollomics Class A is measured differently than its book value, which is the value of Apollomics that is recorded on the company's balance sheet. Investors also form their own opinion of Apollomics' value that differs from its market value or its book value, called intrinsic value, which is Apollomics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Apollomics' market value can be influenced by many factors that don't directly affect Apollomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Apollomics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Apollomics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Apollomics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Apollomics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Apollomics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Apollomics.
| 10/31/2025 |
| 01/29/2026 |
If you would invest 0.00 in Apollomics on October 31, 2025 and sell it all today you would earn a total of 0.00 from holding Apollomics Class A or generate 0.0% return on investment in Apollomics over 90 days. Apollomics is related to or competes with SeaStar Medical, Moleculin Biotech, Lunai Bioworks, Tharimmune, BioLineRx, GeoVax Labs, and Adlai Nortye. Apollomics is entity of United States. It is traded as Stock on NASDAQ exchange. More
Apollomics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Apollomics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Apollomics Class A upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.02) | |||
| Maximum Drawdown | 44.38 | |||
| Value At Risk | (17.51) | |||
| Potential Upside | 17.08 |
Apollomics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Apollomics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Apollomics' standard deviation. In reality, there are many statistical measures that can use Apollomics historical prices to predict the future Apollomics' volatility.| Risk Adjusted Performance | 6.0E-4 | |||
| Jensen Alpha | (0.01) | |||
| Total Risk Alpha | (0.97) | |||
| Treynor Ratio | 0.0717 |
Apollomics January 29, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 6.0E-4 | |||
| Market Risk Adjusted Performance | 0.0817 | |||
| Mean Deviation | 6.94 | |||
| Coefficient Of Variation | (8,542) | |||
| Standard Deviation | 9.58 | |||
| Variance | 91.78 | |||
| Information Ratio | (0.02) | |||
| Jensen Alpha | (0.01) | |||
| Total Risk Alpha | (0.97) | |||
| Treynor Ratio | 0.0717 | |||
| Maximum Drawdown | 44.38 | |||
| Value At Risk | (17.51) | |||
| Potential Upside | 17.08 | |||
| Skewness | (0.25) | |||
| Kurtosis | 1.84 |
Apollomics Class A Backtested Returns
Apollomics appears to be unstable, given 3 months investment horizon. Apollomics Class A secures Sharpe Ratio (or Efficiency) of 0.0897, which signifies that the company had a 0.0897 % return per unit of risk over the last 3 months. By analyzing Apollomics' technical indicators, you can evaluate if the expected return of 0.72% is justified by implied risk. Please makes use of Apollomics' Risk Adjusted Performance of 6.0E-4, mean deviation of 6.94, and Standard Deviation of 9.58 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Apollomics holds a performance score of 7. The firm shows a Beta (market volatility) of -1.7, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Apollomics are expected to decrease by larger amounts. On the other hand, during market turmoil, Apollomics is expected to outperform it. Please check Apollomics' potential upside, as well as the relationship between the rate of daily change and period momentum indicator , to make a quick decision on whether Apollomics' price patterns will revert.
Auto-correlation | 0.34 |
Below average predictability
Apollomics Class A has below average predictability. Overlapping area represents the amount of predictability between Apollomics time series from 31st of October 2025 to 15th of December 2025 and 15th of December 2025 to 29th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Apollomics Class A price movement. The serial correlation of 0.34 indicates that nearly 34.0% of current Apollomics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.34 | |
| Spearman Rank Test | 0.24 | |
| Residual Average | 0.0 | |
| Price Variance | 3.45 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Apollomics Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Apollomics Class A reported net income of (53.86 Million). This is 115.78% lower than that of the Biotechnology sector and 176.89% lower than that of the Health Care industry. The net income for all United States stocks is 109.43% higher than that of the company.
Apollomics Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Apollomics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Apollomics could also be used in its relative valuation, which is a method of valuing Apollomics by comparing valuation metrics of similar companies.Apollomics is currently under evaluation in net income category among its peers.
Apollomics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Apollomics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Apollomics' managers, analysts, and investors.Environmental | Governance | Social |
Apollomics Fundamentals
| Return On Equity | -2.34 | ||||
| Return On Asset | -0.75 | ||||
| Operating Margin | 10.07 % | ||||
| Current Valuation | 38.73 M | ||||
| Shares Outstanding | 2.14 M | ||||
| Shares Owned By Institutions | 0.67 % | ||||
| Number Of Shares Shorted | 15.6 K | ||||
| Price To Book | 8.12 X | ||||
| Price To Sales | 6.15 X | ||||
| Revenue | 198 K | ||||
| Gross Profit | 198 K | ||||
| EBITDA | (41.05 M) | ||||
| Net Income | (53.86 M) | ||||
| Total Debt | 966 K | ||||
| Book Value Per Share | 4.41 X | ||||
| Cash Flow From Operations | (28.74 M) | ||||
| Short Ratio | 0.28 X | ||||
| Earnings Per Share | (52.80) X | ||||
| Target Price | 2.0 | ||||
| Number Of Employees | 13 | ||||
| Beta | 1.81 | ||||
| Market Capitalization | 44.92 M | ||||
| Total Asset | 13.1 M | ||||
| Retained Earnings | (700.82 M) | ||||
| Working Capital | 2.87 M | ||||
| Net Asset | 13.1 M |
About Apollomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Apollomics Class A's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Apollomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Apollomics Class A based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Apollomics Piotroski F Score and Apollomics Altman Z Score analysis. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Will Biotechnology sector continue expanding? Could Apollomics diversify its offerings? Factors like these will boost the valuation of Apollomics. If investors know Apollomics will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Apollomics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (52.80) | Revenue Per Share | Quarterly Revenue Growth 2.623 | Return On Assets | Return On Equity |
The market value of Apollomics Class A is measured differently than its book value, which is the value of Apollomics that is recorded on the company's balance sheet. Investors also form their own opinion of Apollomics' value that differs from its market value or its book value, called intrinsic value, which is Apollomics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Apollomics' market value can be influenced by many factors that don't directly affect Apollomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Apollomics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Apollomics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Apollomics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.